Affordable Access

Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities.

Authors
Type
Published Article
Journal
Archivos españoles de urología
Publication Date
Volume
50
Issue
7
Pages
821–824
Identifiers
PMID: 9350090
Source
Medline
License
Unknown

Abstract

Our findings suggest that systematic sextant PNbx for PSA > 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.

Statistics

Seen <100 times